Abbott Laboratories

▲ Bull Case

• ◆Libre recall resolves cleanly by Q2 2026: Adhesive reformulation clears FDA without additional issues; Libre 4 next-gen launch re-accelerates Diabetes Care from flat to 18%+; European national formulary holders confirm Libre preferred status; Libre Lingo (non-diabetic wellness CGM) adds incremental $500M+ TAM. EPS upside: +$0.50–0.75/share vs. base by FY2027.
• ◆Cologuard international is multi-billion optionality not in consensus: Exact Sciences as a standalone company lacked the international commercial infrastructure to pursue non-US reimbursement. Abbott has it—Alinity is already reimbursed in Germany, UK, France, Japan, Australia. If 3–4 markets achieve Cologuard reimbursement by FY2028, this adds $500M–1.5B in incremental revenue and $0.25–0.50/share in EPS.
• ◆Volt PFA captures 25%+ of the fastest-growing cardiac ablation technique: PFA is only ~5% penetrated in total AF ablation procedures. Abbott's Volt, integrated with EnSite X cardiac mapping (40–45% of EP labs already use), creates an installed-base pull-through advantage. If Volt reaches 25–30% PFA share vs. consensus 15–20% by FY2028, this adds $300–500M revenue above base.

▼ Bear Case

• ◆NEC litigation escalates beyond base case: Thousands of pending cases; April 2026 verdict of $53M is a template. If 50–100 additional cases reach trial at similar outcomes, aggregate liability is $3–5B+. A $4–5B settlement would consume 1+ year of FCF, potentially pressure the credit rating, and destroy confidence in the cash flow framework underlying the Exact Sciences acquisition thesis.
• ◆Libre recall extends and Dexcom permanently gains European formulary share: European national health systems (NHS, GKV, CNAM) operate on multi-year formulary cycles. If they use the recall as a trigger to evaluate Dexcom alternatives and Dexcom offers comparable total cost of care, Abbott could lose preferential formulary positions built over a decade. A 20–30% permanent reduction in European CGM market share would reduce Libre international revenue by ~$1.5–2.0B—an irreversible structural impairment.
• ◆Exact Sciences integration disappoints and absorbs FCF: If Cologuard's 200+ person sales force underperforms under Abbott management and growth decelerates from 17% to 10%, the EPS accretion timeline extends from 2 to 3–4 years—and the $1.4B/yr interest expense becomes pure dilution rather than a 'bridge cost' thesis.

“The debate is: 'Is NEC a $1–2B manageable reserve or a $4–5B potential impairment?' The sell-side consensus (28 of 33 analysts Buy/Outperform; average PT ~$150–155) models NEC at $1–2B aggregate and views Libre recall as a 2-quarter interruption. Bears (5 analysts with Neutral/Underweight) model NEC at $3–5B and see Libre recall as potentially damaging European formulary relationships. The secondary debate addresses whether the Exact Sciences acquisition creates a durable Cologuard platform or dilutive financial engineering. A Q3 2026 NEC settlement announcement in the $1.5–2.5B range + simultaneous Libre re-acceleration to 13%+/yr would shift 80%+ of the street to Buy and drive a re-rating from 20x to 24x FY2027E.”

• ◆Q2 2026 earnings: Libre recall resolution announcement (July 2026, 60% probability)
• ◆Exact Sciences first full-quarter contribution validates integration (July 2026, 70% probability)
• ◆Volt PFA market share first commercial data disclosed (Q2–Q3 2026, 65% probability)
• ◆NEC settlement framework announcement removes overhang (H2 2026, 35% probability)
• ◆Cologuard international reimbursement in Germany or UK (2026–2027, 25% probability)
• ◆Libre Lingo non-diabetic CGM traction data (FY2026–2027, 30% probability)
• ◆Cologuard Plus FDA approval (2026, 75% probability)
• ◆AVEIR dual-chamber leadless pacemaker EU approval (FY2026–2027, 60% probability)

• ◆NEC aggregate litigation >$3B (20–25% probability; VERY HIGH severity): –$10–20/share equity; credit rating pressure
• ◆Libre recall extends to Q1 2027; European formulary loss (20% probability; HIGH severity): –$15–25/share; permanent structural damage
• ◆Exact Sciences integration failure; Cologuard growth <10% (15% probability; HIGH severity): –$8–12/share; EPS accretion delayed 2+ years
• ◆Dexcom G8 accelerates US market share gain (25% probability; MEDIUM severity): –$5–8/share via Libre US mix shift
• ◆CMS reimbursement cuts—Cologuard coverage narrowing (10% probability; HIGH severity): –$10–15/share if broad coverage restricted
• ◆GLP-1 drugs reduce Type 2 CGM demand (15% probability; MEDIUM severity): –$3–6/share; multi-year headwind
• ◆China geopolitical—EPD/device revenue disruption (10% probability; MEDIUM severity): –$3–5/share